Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

Although the results obtained from ECOG E5194 cohort 1 (criteria: mammographically detected low- or intermediate-grade DCIS, measuring less than 2.5 cm with margins 3 mm) and RTOG 9804 trial (the same enrolled clinicopathological features to cohort 1 of ECOG E5194 trial) demonstrated that the 7-year ipsilateral breast tumor recurrence (IBTR) …

mammogram
breast-conserving surgery
tamoxifen
carcinoma in situ
breast tumor
  • 13 views
  • 14 Feb, 2022
  • 1 location
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ

The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).

  • 0 views
  • 26 Sep, 2021
  • 1 location
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers. Decision support tools are

Accepts healthy volunteers
  • 0 views
  • 23 Mar, 2022
  • 19 locations
Ruxolitinib for Premalignant Breast Disease (TBCRC042)

This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery …

carcinoma in situ
ductal hyperplasia
breast biopsy
lobular carcinoma
neutrophil count
  • 49 views
  • 23 May, 2022
  • 7 locations
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI)

This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer that will: 1) significantly reduce the duration of treatment and can be completed in one-week (5 working days) and 2) MRI-guided radiotherapy (MRIdian) would limit the volume of normal tissue radiated …

breast-conserving surgery
invasive carcinoma
mammogram
ductal carcinoma in situ
carcinoma in situ
  • 1 views
  • 26 May, 2022
  • 1 location
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

Single-arm, phase 2 study evaluating hypofractionated irradiation of breast and regional nodes in women with breast cancer. Patients will be grouped in 3 surgery-related treatment groups: 1) An intact breast following lumpectomy; 2) plans for loco regional external beam radiotherapy (EBRT) following mastectomy (with or without plans for reconstruction); and …

ductal carcinoma
mastectomy
breast tumor
hysterectomy
sentinel lymph node biopsy
  • 18 views
  • 26 Dec, 2021
  • 2 locations
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

This randomized phase III trial studies metformin hydrochloride to see how well it works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may prevent …

mammogram
tamoxifen
mastectomy
carcinoma in situ
metformin hydrochloride
  • 247 views
  • 29 Apr, 2022
  • 5 locations
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

carboplatin
dcis
breast cancer
absolute neutrophil count
estrogen receptor
  • 11 views
  • 24 Feb, 2022
  • 3 locations
High-Risk Breast Duct Epithelium

/2 or other hereditary genes mutation carriers. Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or lobular carcinoma in situ. Women

ductal carcinoma in situ
BRCA1
ductal carcinoma
estradiol
mammogram
  • 8 views
  • 16 May, 2022
  • 1 location